Daniel Santillano, MD
Internal Medicine · San Antonio, TXNPI 1508903899
Payments from drug & device makers
Across 764 payments — averaging $2767.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1M
- Eli Lilly$335K
- Regeneron$326K
- Madrigal Pharmaceuticals$181K
- Dexcom, Inc.$175K
- Gilead$31K
- plus $28K from 6 others
Across 11 payments — averaging $14,929 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$162K
- Corcept Therapeutics$2K
What the payments were for
- Travel & lodging$2,39469%
- Food & beverage$79623%
- Other$2948%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 593 | $1,038,590 |
| Eli Lilly | 8 | $335,262 |
| Regeneron | 80 | $326,016 |
| Madrigal Pharmaceuticals | 40 | $180,628 |
| Dexcom, Inc. | 12 | $174,882 |
| Gilead | 5 | $31,085 |
| GSK | 4 | $13,815 |
| Amgen | 1 | $10,482 |
| Merck | 17 | $2,876 |
| Welch Allyn | 1 | $294 |
| Abbott | 1 | $161 |
| Novo Nordisk | 2 | $153 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELI 280$294
- AMPLATZER TALISMAN$161
How this compares
$2,114,245 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 73 | $463 |
| Rosuvastatin Calcium | 54 | $416 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 40 | $342 |
| ClopidogrelClopidogrel Bisulfate | 35 | $319 |
| Amiodarone Hcl | 30 | $245 |
| Tramadol Hcl | 53 | $114 |
| Metoprolol Tartrate | 19 | $51 |
| Carvedilol | 16 | $26 |
| Furosemide | 17 | $18 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Antonio
- Robert BassSan Antonio$25.6M
- Hernan SalazarSan Antonio$18.5M
- Dennis RuffSan Antonio$7.5M
- Cassandra KeySan Antonio$5.6M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.